Many of the medications used in our study were older-generation GLP-1s that have less potent effects on weight loss
No, GLP-1 receptor agonists are not specifically contraindicated in Crohn's disease, but caution is advised in patients with active or severe gastrointestinal disease
Electrolyte+ Hydration + energy support
Three years ago, the equivalent numbers were $150+ per month insured and $1,000+ uninsured
According to FDA labeling, the common side effects include: Gastrointestinal effects (with frequencies varying by dose): Nausea (12-30% of patients, often most prominent during dose escalation) Diarrhea (7-22%) Vomiting (2-10%) Constipation (5-17%) Abdominal pain or discomfort (5-10%) Decreased appetite (5-10%) Dyspepsia/indigestion (2-9%) Gastroesophageal reflux disease (1-5%, more common in weight management indication) Eructation/belching (more common in weight management indication) These gastrointestinal symptoms typically occur early in treatment or following dose increases and often diminish over time as the body adjusts to the medication
Yes, the gelatin trick is supported by scientific research
